Consensus coding sequences of human breast and colorectal cancers
Analysis of 13,023 genes in 11 breast and 11 colorectal cancers revealed that individual tumors accumulate an average of ˜90 mutant genes but that only a subset of these contribute to the neoplastic process. Using stringent criteria to delineate this subset, we identified 189 genes (average of 11 per tumor) that were mutated at significant frequency. The vast majority of these genes were not known to be genetically altered in tumors and are predicted to affect a wide range of cellular functions, including transcription, adhesion, and invasion. These data define the genetic landscape of two human cancer types, provide new targets for diagnostic and therapeutic intervention and monitoring.
1. A method of testing a human sample, comprising the step of:
testing a test colorectal sample of the human by subjecting the sample to a reaction, and detecting a cysteine codon or residue in a gene or its encoded cDNA or protein at IDH1 codon or residue 132.
2. The method of claim 1 wherein a cysteine codon is detected at IDH1 codon 132 in the gene.
3. The method of claim 1 wherein a cysteine codon is detected at IDH1 codon 132 in the encoded cDNA.
4. The method of claim 1 wherein a cysteine residue is detected at IDH1 residue 132 in the protein.
5. The method of claim 1 wherein a sequencing reaction is run on all or a part of IDH1 gene including codon 132.
6. The method of claim 1 wherein the step of testing comprises a step of contacting (a) a probe specific for IDH1 with a cysteine codon at codon 132 with (b) the test colorectal sample.
7. The method of claim 1 wherein the step of testing comprises a step of contacting (a) a primer specific for IDH1 with a cysteine codon at codon 132 with (b) the test colorectal sample.
8. The method of claim 1 wherein the step of testing comprises a step of contacting (a) an antibody specific for IDH1 with a cysteine residue at residue 132 with (b) the test colorectal sample.
9. The method of claim 1 wherein the step of testing comprises a hybridization reaction between the test colorectal sample and a primer or probe.
10. The method of claim 1 wherein the step of testing comprises a primer extension reaction in which a primer is hybridized to the test colorectal sample and the primer is extended, wherein the extended primer comprises a cysteine codon at codon 132.
11. A method of characterizing a colorectal sample in a human, comprising the steps of:
testing a suspected colorectal cancer metastasis sample of the human by subjecting the sample to a reaction, and detecting in a gene or its encoded cDNA or protein a cysteine codon or residue at codon or residue 132 of IDH1 of the sample.
12. The method of claim 11 wherein a cysteine codon at codon 132 of IDH1 is detected in the gene.
13. The method of claim 11 wherein a cysteine codon at codon 132 of IDH1 is detected in the encoded cDNA.
14. The method of claim 11 wherein a cysteine residue at residue 132 of IDH1 is detected in the protein.
15. The method of claim 11 wherein all or a part of IDH1 gene comprising codon 132 is subjected to a sequencing reaction.
16. The method of claim 11 wherein the step of testing employs a probe specific for IDH1 with a cysteine codon at codon 132.
17. The method of claim 11 wherein the step of testing employs a primer specific for IDH1 with a cysteine codon at codon 132.
18. The method of claim 11 wherein the step of testing employs an antibody specific for IDH1 with a cysteine residue at residue 132.
19. The method of claim 11 wherein the step of testing employs a hybridization reaction with a probe or primer.
20. The method of claim 11 wherein the step of testing employs a primer extension reaction in which a primer is hybridized to the test colorectal sample and the primer is extended, wherein the extended primer comprises a cysteine codon at codon 132.
21. A method for testing candidate or known anti-cancer therapeutics in a group of humans with colorectal cancer, comprising the steps of:
testing for a cysteine codon or amino acid residue at IDH1 codon or residue 132 in a test sample of each of the humans by subjecting the test samples to a reaction;
detecting said codon or amino acid residue in a first subgroup of the humans;
testing sensitivity to a candidate or known anti-cancer therapeutic of the first subgroup; and
testing sensitivity to the candidate or known anti-cancer therapeutic of a second subgroup that does not have a cysteine codon or amino acid residue at codon or amino acid residue 132 of IDH1.
22. The method of claim 21 wherein a cysteine codon at codon 132 of IDH1 is detected in the gene.
23. The method of claim 21 wherein a cysteine codon at codon 132 of IDH1 is detected in the cDNA.
24. The method of claim 21 wherein a cysteine residue at residue 132 of IDH1 is detected in the protein.
25. The method of claim 21 wherein a sequencing reaction is run on all or a part of IDH1 gene comprising codon 132.
26. The method of claim 21 wherein the step of testing employs a probe specific for IDH1 with a cysteine codon at codon 132.
27. The method of claim 21 wherein the step of testing employs a primer specific for IDH1 with a cysteine codon at codon 132.
28. The method of claim 21 wherein the step of testing employs an antibody specific for IDH1 with a cysteine residue at residue 132.
29. The method of claim 21 wherein the step of testing employs a hybridization reaction with a probe or primer.
30. The method of claim 21 wherein the step of testing employs a primer extension reaction in which a primer is hybridized to the test colorectal sample and the primer is extended, wherein the extended primer comprises a cysteine codon at codon 132.